Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Entity Listing, Par Value Per Share Increase decrease in operating lease right of use asset. Schedule of Operating Leases Of Lessee [Table Text Block] Milestone payments. Discovery Collaboration Agreements [Member] XOMA [Member] License fees. Alkem Agreement [ Member] Cellca Agreement [Member] Description of milestone payments. Annual license fee payment. Commerical product license fee payment obligation. Development license fee payment obligation. The Brink Agreement [Member] Payment of annual license fee. Cell line storage fee. Invivo Gen Agreement [Member] ProteoNic Agreement [Member] Agreements description. SOC Agreement [Member] Navigo Agreement [Member] Navigo Proteins GmbH [Member] Evaluation milestone recognized. Proceeds for negotiate license agreement. License Agreement [Member] Performance obligation. October Offering [Member] Underwriters [Member] Prefunded Warrant [Member] Common Warrant [Member] June Twenty Twenty Four Inducement Offer [Member] Purchase and Registration Rights Agreement [Member] Volume weighted average price discount percentage. Purchase Agreement [Member] Underwriting Agreement [Member] Chardan Capital Markets LLC [Member] Registered Direct Offering [Member] Incentive tax receivable current. Dr Richard Kenney [Member] Business Combination Agreement [Member] Common Stock Warrants August 2021 [Member] Underwriter Warrants August 2021 [Member] Chanticleer Warrants [Member] Series C Warrants [Member] Series 3 Warrants [Member] Common Stock Warrants February 2023 [Member] Underwriter Warrant February 2023 [Member] Common Stock Private Placement Warrants June 2023 [Member] Placement Agent Warrants June 2023 [Member] Common Stock Warrants October 2023 [Member] Underwriter Warrants October 2023 [Member] Placement Agent Warrants June 2024 [Member] Common Stock Warrants June 2024 [Member] Common Stock Warrants November 2024 [Member] Stock retired during period value reverse stock splits. Stock issued during period value net share settlement of warrants. Stock issued during period value exercise and modification of warrants. Common Stock PIPE Warrants December 2024 [Member] CommonStockWarrants July 2025 [Member] Common stock warrants PIPE July 2025 [Member] Stock retired during period shares reverse stock splits. Stock issued during period value net share settlement of warrants, shares. Stock issued during period shares exercise and modification of warrants. Common stock warrants July 2025 One [Member] Stock issued during period value exercise of warrants. StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesStockIssuedDuringPeriodValueConversionOfConvertibleSecurities. Common Stock Warrants [Member] Sale of common stock, net of issuance costs. Sale of common stock, net of issuance costs by shares. Exercise of warrants by shares. Acquired in-process research and development. Financing costs. Payment of deferred offering costs. Net settlement of warrants. Changes in incentive tax receivable. Inducement Offer Letter Agreements [Member] Stock issued during period value shares released from abeyance. New Common Stock [Member] Existing Warrant [Member] New Common Stock Warrant [Member] Existing Warrant Issued in June 2023 [Member] Placement Agent [Member] Holder [Member] 2020 Omnibus Equity Incentive Plan [Member] Restricted Stock Awards (RSA) [Member] Financing costs in accounts payable. Conversion of convertible notes into preferred stock. In process research and development in accounts payable. Warrant issuance costs in accounts payable. Schedule Of Nonvested Restricted Stock Awards Activity [Table Text Block] Incentive Tax Receivbale [Policy Text Block] Other Income [Policy Text Block] Deferred tax assets amortization Deferred tax assets operting lease liability Deferred tax assets tax deferred expense section disallowed interest expense. Deferred tax liabilities right of use asset. Proceeds from sale of state net operating losses. Proceeds from sale of unused research and development tax credits. Research and Development Tax Incentive Program [Member] Effective income tax rate reconciliation permanent differences. Change in foreign exchange rates. Effective income tax rate reconciliation sale of state net operating losses and research and development credits. Cash refund expected to be received. Prefunded October 2023 Warrants [Member] Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by foreign withholding taxes. Excise tax. Corporate alternative tax percentage. Accrued compensation and benefits, current. Accrued research and development current. Clinical expenses. Non clinical expenses. Consulting fees. Subscription Agreement [Member] Liquidation preference value. Unvested Restricted Stock Units And Awards [Member] Underwriter Warrants February 2023 [Member] Other research and development. Common stock avialable to be sold. Common stock warrants July 2025 Two [Member] Beginning balance Ending balance